PubRank

Daniel Zips

Author PubWeight™ 32.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006 1.61
2 Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 2006 1.32
3 Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 2009 1.23
4 Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007 1.13
5 PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest 2010 1.09
6 Cancer stem cells and radiotherapy. Int J Radiat Biol 2009 1.06
7 Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol 2008 1.01
8 Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007 1.00
9 EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res 2012 0.96
10 Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem 2002 0.95
11 Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 2011 0.94
12 A strategy for multimodal deformable image registration to integrate PET/MR into radiotherapy treatment planning. Acta Oncol 2013 0.93
13 Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat Biol 2009 0.92
14 Quality of training in radiation oncology in Germany. Results of a 2006 survey. Strahlenther Onkol 2008 0.92
15 Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 2006 0.91
16 GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol 2013 0.91
17 Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010 0.90
18 Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014 0.89
19 BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. Radiat Oncol 2014 0.87
20 Molecular targeting in radiotherapy of lung cancer. Lung Cancer 2004 0.84
21 Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother Oncol 2011 0.84
22 Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity. Radiother Oncol 2009 0.83
23 Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer 2013 0.83
24 Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 2005 0.82
25 Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. Radiother Oncol 2010 0.81
26 Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts. Radiother Oncol 2011 0.80
27 The future of IGRT - cost benefit analysis. Acta Oncol 2008 0.80
28 Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images. Acta Oncol 2013 0.80
29 Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. Nucl Med Biol 2002 0.79
30 The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiother Oncol 2009 0.79
31 Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy. Strahlenther Onkol 2007 0.78
32 Monitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation. Int J Radiat Oncol Biol Phys 2012 0.78
33 Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer. Int J Hyperthermia 2016 0.78
34 PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother Oncol 2008 0.77
35 Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 2005 0.77
36 Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma? Radiother Oncol 2005 0.77
37 Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol 2005 0.76
38 Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. Radiother Oncol 2009 0.75
39 Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach? Cancers (Basel) 2011 0.75
40 Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. Strahlenther Onkol 2004 0.75